Literature DB >> 30838264

Paraneoplastic Atypical Parkinsonism with Anti-CRMP5 Antibodies and Severe Caudate and Putaminal Hypometabolism on 18-Fluorodeoxyglucose Positron Emission Tomography of the Brain.

Siew Mei Yap1, Tim Lynch1, Peter MacMahon2, Brian Murray1.   

Abstract

Entities:  

Keywords:  18‐fluorodeoxyglucose positron emission tomography (18FDG PET) brain; caudate and putamen; collapsin response mediator protein 5 (CRMP5); paraneoplastic Parkinsonism

Year:  2016        PMID： 30838264      PMCID： PMC6353453          DOI： 10.1002/mdc3.12370

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN： 2330-1619


× No keyword cloud information.
  9 in total

1.  Localization of CRMP5 mRNA by in situ hybridisation during development of the mouse forebrain.

Authors:  David McLaughlin; Marina Vidaki; Domna Karagogeos
Journal:  Neurosci Lett       Date:  2007-12-15       Impact factor: 3.046

Review 2.  PET/CT in diagnosis of movement disorders.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

3.  CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity.

Authors:  Z Yu; T J Kryzer; G E Griesmann; K Kim; E E Benarroch; V A Lennon
Journal:  Ann Neurol       Date:  2001-02       Impact factor: 10.422

4.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

Review 5.  Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates.

Authors:  Sandip Basu; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2008-02-23       Impact factor: 3.488

Review 6.  Movement disorders caused by medical disease.

Authors:  Brandon Barton; S Elizabeth Zauber; Christopher G Goetz
Journal:  Semin Neurol       Date:  2009-04-15       Impact factor: 3.420

Review 7.  Paraneoplastic neurological syndromes.

Authors:  F Leypoldt; K-P Wandinger
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

8.  Severe parkinsonism associated with anti-CRMP5 antibody-positive paraneoplastic neurological syndrome and abnormal signal intensity in the bilateral basal ganglia.

Authors:  Satoru Tada; Mitsuru Furuta; Kei Fukada; Daisuke Hirozawa; Misa Matsui; Futoshi Aoike; Tatsusada Okuno; Jin-Ichi Sawada; Hideki Mochizuki; Takanori Hazama
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-09-15       Impact factor: 10.154

9.  Analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism.

Authors:  Lucia V Schottlaender; James M Polke; Helen Ling; Nicola D MacDoanld; Arianna Tucci; Tina Nanji; Alan Pittman; Rohan de Silva; Janice L Holton; Tamas Revesz; Mary G Sweeney; Andy B Singleton; Andrew J Lees; Kailash P Bhatia; Henry Houlden
Journal:  Neurobiol Aging       Date:  2014-08-27       Impact factor: 4.673
  9 in total
  2 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

2.  Antibody-Negative Paraneoplastic Limbic Encephalitis, Parkinsonism, Hypothermia, and Narcolepsy Associated with Endometrial Carcinoma.

Authors:  Declan Brennan; Olwen C Murphy; Conor Fearon; Francesca Brett; Brian Murray; Tim Lynch
Journal:  Mov Disord Clin Pract       Date:  2020-01-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.